Uncategorized

Horizon Therapeutics plc Initiates Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating Teprotumumab for the Treatment of Active Thyroid Eye Disease (TED)

by Business Wire • 2022/02/23 • 0 Comments

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announces the initiation of a Phase 3 trial (OPTIC-J) in Japan evaluating teprotumumab for the treatment of active TED.

← NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China

EyeSouth Partners Affiliates With Gadsden Eye Associates, Representing the Network’s 29th Affiliation and Second in Alabama →

Post navigation